Description
Anti-CD274 Antibody, Non-Fucosylated (BioBet-119ZP) is a human monoclonal IgG1, κ antibody against CD274. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Cancers, ovarian, gastric, non-small cell lung (NSCLC), metastatic, Solid tumors
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CD274 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Alternative Names
Programmed cell death 1 ligand 1; B7H1; B7-H1; PDL1; PD-L1; PDCD1L1; B7 homolog 1; B7 homologue 1
Cellular Localization
Plasma membrane, Endosome
Involvement in Disease
Diseases associated with CD274 include Testicular Lymphoma and Smoldering Myeloma.
Related Pathways
Its related pathways are Innate Immune System and Class I MHC mediated antigen processing and presentation.
Function
It plays a key role in inducing and maintaining immune tolerance to oneself. As a ligand for the inhibitory receptor PDCD1/PD-1, it regulates the activation threshold of t cells and limits the effector response of t cells. Through an unknown activation receptor, it is possible to stimulate a subset of T cells to mainly produce interleukin 10 (IL10). Tumors use the pdcd1 mediated inhibitory pathway to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival. The interaction with PDCD1/PD-1 inhibits the effector function of cytotoxic T lymphocytes (CTLs) (similar). The blockade of the pdcd1 mediated pathway leads to the reversal of the exhausted T cell phenotype and the normalization of the anti-tumor response, which provides a theoretical basis for cancer immunotherapy (through similarity).
Post-translational modifications
1.Ubiquitinated; STUB1 likely mediates polyubiquitination of PD-L1/CD274 triggering its degradation 2.Glycosylation at Asn35, Asn192, Asn200, and Asn219 3.Modification sites at PhosphoSitePlus
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
BioBet-119ZP
Description
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to CD274. Durvalumab is a human monoclonal antibody that can be potentially used in the treatment of Cancers, non-small cell lung (NSCLC), Solid tumors, bladder, urothelial.
Antibody Indication
Cancers, ovarian, gastric, non-small cell lung (NSCLC), metastatic, Solid tumors
